Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Special Features of Adaptive Immunity

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CIMatcher: Cross-scale interaction matcher for accurate local feature matching.

Neural networks : the official journal of the International Neural Network Society·2026

Same author

Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.

Cell reports. Medicine·2026

Same author

Targeting TMED4 enhances CD8<sup>+</sup> T cell function and CAR T cell efficacy in solid tumors through the IRE1α-autophagy axis.

Science advances·2026

Same author

Low-Dose Stereotactic Body Radiation Therapy-Based Radiation Therapy Followed by Pembrolizumab and Chemotherapy for Potentially Resectable Non-Small Cell Lung Cancer: A Phase 1b Study.

International journal of radiation oncology, biology, physics·2026

Same author

Description of <i>Ornithinimicrobium pulveris</i> sp. nov. and <i>Ornithinimicrobium carbonis</i> sp. nov., isolated from a coal mine working environment.

International journal of systematic and evolutionary microbiology·2026

Same author

Multidimensional synergistic inhibition of Clostridium perfringens spores by nisin and tea polyphenols: a systematic insight from interference germination to metabolic imbalance.

Food research international (Ottawa, Ont.)·2026

Search research articles

Related Experiment Video

Updated: Sep 17, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

BAFF-based trifunctional T-cell engagers trigger robust tumor immunity against B-cell malignancies.

Shuhong Li¹, Licai Shi¹, Qiaoru Guo¹

¹State Key Laboratory of Chemical Oncogenomics, Shenzhen Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China.

|June 27, 2025

Summary

New T-cell engagers (TCEs) using BAFF ligands show promise for B-cell malignancies. The optimal TriBAFF/CD3/ABDCon construct effectively targets tumors and T cells, outperforming existing therapies.

Keywords:

B-cell malignancy T-cell engager antibody engineering immune escape multispecific antibody natural ligand

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Experiment Videos

Last Updated: Sep 17, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Area of Science:

Immunology
Oncology
Biotechnology

Background:

T-cell engagers (TCEs) are advanced protein-engineered therapeutics with significant clinical success in B-cell malignancies.
Multispecific TCEs offer a strategy to overcome tumor heterogeneity and antigen escape, but format design remains a challenge.

Purpose of the Study:

To engineer and evaluate various BAFF-based T-cell engager formats targeting BAFF receptors (BAFFR, BCMA, TACI) for B-cell malignancies.
To identify an optimal construct for enhanced T-cell mediated cytotoxicity and tumor eradication.

Main Methods:

Engineered BAFF-based TCEs with different formats, incorporating anti-CD3 Fab or IgG domains fused with BAFF ligands.
Varied constructs in valency and included long-acting elements like Fc domains or albumin binding domain consensus sequence (ABDCon).
Assessed cytotoxicity and tumor burden control in B-cell malignancy models.

Main Results:

Fc domain inclusion did not improve tumor eradication; valency and spatial configuration significantly impacted cytotoxicity.
The trifunctional TriBAFF/CD3/ABDCon construct, with an anti-CD3 Fab backbone and BAFF/ABDCon fusions, proved optimal.
TriBAFF/CD3/ABDCon demonstrated superior tumor control and tolerability in B-cell malignancy models compared to blinatumomab and BAFF-based CAR-T cells.

Conclusions:

Natural ligands can be effectively utilized as antibody-targeting modules in T-cell engager design.
The TriBAFF/CD3/ABDCon format provides a promising next-generation multispecific TCE for improved treatment of B-cell malignancies and potentially other cancers.